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ABSTRACT
In this report we describe a rare case of primary hepatic diffuse large B cell lymphoma in a 
67-year-old man who presented with abdominal pain, deteriorated liver function, elevated 
lactate dehydrogenase. He was found to have diffuse nodular intrahepatic space-occupying 
lesion with normal α-fetoprotein and carcino-embryogenic antigen. The final diagnosis was 
made by percutaneous biopsy of the liver as the clinical manifestation not consistent with 
common liver diseases. The patient was treated with R-CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisone) without surgical resection with a favorable re-
sponse. However, serious complication was occurred after 4 cycles of chemotherapy, and the 
patient finally died of concurrent acute respiratory distress syndrome.
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Introduction
Primary hepatic lymphoma (PHL) is an unusual form of 
non-Hodgkin's lymphoma that usually presents with consti-
tutional symptoms, hepatomegaly and signs of cholestatic 
jaundice  without  lymph  node  and  extrahepatic  (.i.e.,  the 
spleen, bone marrow and other lymphoid tissue) lymphoma 
proliferation at early stage of the disease (1). The prevalence of 
PHL was 0.4% among extranodal non-Hodgkin's lymphoma, 
and 0.016% among all non-Hodgkin's lymphoma (2). Because 
of its rarity, non-specific clinical symptoms, laboratory and 
imaging performance, PHL was often misdiagnosed as hepa-
titis, primary liver cancer or metastatic tumor. In this case 
report, we present a patient with pathologically confirmed 
primary hepatic diffuse large B cell lymphoma.
Case presentation
A 67-year-old Chinese man was hospitalized for fatigue, an-
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orexia, yellowish discoloration of skin and sclera, and right 
upper quadrant abdominal pain. The patient had no com-
plaints of fever, significant weight loss. He did not have his-
tory of smoking, alcohol consumption and drugs abuse. He 
had a history of cholecystectomy at the age of 45. Physical 
examination revealed no abnormal findings except for ten-
derness on percussion on liver and edema in both lower ex-
tremities. There was no palpable superficial lymphadenopa-
thy.  He  had  no  hepatosplenomegaly.  Laboratory  findings 
showed  deteriorated  liver  function,  elevated  blood  lipids 
and lactate dehydrogenase (LDH) (Table 1). Serologic tests for 
hepatitis A, B and C were negative; serum α-fetoprotein (AFP) 
and  carcinoembryonic  antigen  (CEA)  levels  were  normal. 
Immunoglobulin levels were normal without any monoclo-
nal peak in the plasma or urine electrophoresis. Abdominal 
ultrasound and computed tomography (CT) revealed diffuse 
occupying nodules in liver (Figure 1A). Subsequent magnetic 
resonance imaging (MRI) revealed diffuse lesions that were 
hypointense  on  T1  and  hyperintense  on  T2-weighted  im-
ages (Figure 1B). There was no evidence of biliary or pancre-
atic disease, splenomegaly or abdominal lymphadenopathy. 
Bone  marrow  biopsy  demonstrated  normal  proliferation 
and  maturation  of  all  cell  lines.  There  was  no  malignant Hepat Mon. 2011;11(3):203-205
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infiltration; flowcytometry examination also showed no ob-
vious abnormality of bone marrow. A core liver biopsy was 
performed, showing heavy infiltration composed mainly of 
medium-sized round cells (Figure 2A). The cells were posi-
tive for CD20 and LCA (Figures 2B and 2C), and proliferation 
index was very high with ki67 positive in 90% of cells (Fig-
ure 2D), establishing a diagnosis of diffuse large B-cell lym-
phoma, according to the WHO classification. After discuss-
ing treatment options and the risks of chemotherapy with 
the patient and her family, the patient was then received at-
tenuated chemotherapy (R-CHOP: rituximab 500 mg, cyclo-
phosphamide 400 mg, doxorubicin 40 mg, vincristine 2 mg, 
and prednisone 60 mg). The courses of chemotherapy were 
given every 2–3 weeks. After receiving two more cycles of the 
chemotherapy (rituximab 500 mg, cyclophosphamide 800 
mg, doxorubicin 60 mg, vincristine 2 mg and prednisone 60 
mg), his liver function was improved—the level of LDH was 
decreased (Table 1), and the intrahepatic diffuse tuberculous 
lesions were decreased both in number and size. However, 
after the 4th cycle of the chemotherapy, the patient devel-
oped neutropenia, diarrhea, followed by intestinal bleeding, 
signs of peritonitis, and pneumonia. Unfortunately, his con-
dition got worse rapidly, and the patient finally died of con-
current acute respiratory distress syndrome (ARDS).
Table 1. Laboratory test results
a Laboratory results before the first chemotherapy
b Laboratory results before the second chemotherapy
c Laboratory results before the third chemotherapy
Item
Weeks after the first admission
Reference Values Unit
0 2 3 a 6 b 9 c
Total bilirubin 117.7 286.8 356.8 115.0 20.4 2.0-28.0 µmol/L
Direct bilirubin 97.1 232.4 278.5 93.0 15.0 < 8.8 µmol/L
Alanine transarninase 79 93 109 57 14 < 55 U/L
Aspartate transarninase 139 243 291 54 32 < 46 U/L
Alkaline phosphatase 467 1025 1492 435 127 47-138 U/L
ɣ-glutamyl transferase 637 595 827 342 117 6-46 U/L
Albumin 32.5 26.1 23.6 30.9 34.5 35-55 g/L
Globulin 36.4 38.6 39.7 30.2 20.3 19-34 g/L
Triglyeride 1.89 2.84 3.16 3.19 1.88 0.29-1.83 mmol/L
Cholesterol 6.13 11.06 14.22 10.10 3.07 2.8-5.7 mmol/L
Lactate dehydrogenase 434 513 448 197 211 110-220 U/L
Figure 2. Histological and immunohistochemical photographs of liver tumor. 
(A): Hematoxylin and eosinstaining, 400×; (B): anti-CD20 staining, 400×; (C): anti-
LCA staining, 400×; (D): anti-ki67 staining, 400×
Figure 1. Abdominal computed tomography (A) and T1-weighted magnetic resonance imaging (B), revealing multiple occupying nodules in liver. Neither splenomegaly 
nor abdominal lymphadenopathy was observed.Hepat Mon. 2011;11(3):203-205
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Discussion
Non-Hodgkin’s  lymphoma  is  a  common  malignant  dis-
ease. Liver involvement occurs in 10% of patients and is a sign 
of advanced disease. PHL refers to an extra-nodal lymphoma 
of the liver without involvement of any other organ (e.g., 
lymph node, spleen, etc) (3, 4). The vast majority (67%) of PHL 
patients are middle-aged men who usually present with ab-
dominal pain, nausea and constitutional symptoms (4). PHL 
is notably rare, representing <1% of all extra-nodal lympho-
ma (4). One Chinese study reported that in 446 cases of non-
Hodgkin’s lymphoma, 45 developed liver involvement, of 
which only one had PHL (5). Limited experience showed that 
PHL had non-specific clinical manifestations. Hepatomegaly 
is  found  in  most  patients,  constitutional  symptoms  (e.g., 
fever, night sweats and weight loss) appear in 37%, fever in 
86%, weight loss in 57% and jaundice in 4% (3, 6). In liver, PHL 
may present as a solitary mass (42%) or as multiple lesions 
(50%). Patients with PHL have abnormal liver function tests 
(cholestasis and cytolysis) (7, 8), mostly elevated LDH and al-
kaline phosphatase (ALP) (6, 9). Additionally, hypercalcemia 
is found in 40% of the patients. The cause of PHL is not en-
tirely clear, but may be related to viral hepatitis (10, 11). Hepa-
titis C virus (HCV) infection is found in 20%–60% of patients 
with PHL. The frequent association with HCV suggests that 
this virus may play a role in the pathogenesis of PHL (7, 8). 
PHL is also seen in immunocompromised patients, but the 
relationship between PHL occurrence and immune deficien-
cy has not yet been reported. Our patient had neither hepa-
titis C infection nor signs of immunodeficiency. Therefore, 
we speculated that PHL also could occur in patients without 
any prior liver disease. Diagnosis of PHL requires a liver bi-
opsy compatible with lymphoma and absence of lymphop-
roliferative disease outside the liver. Through analyzing 90 
patients with hepatic lymphoma, Lei Ki (4) proposed the fol-
lowing criteria for the diagnosis of primary hepatic lympho-
ma: 1) the symptoms are mainly caused by liver involvement 
at presentation; 2) no clear evidence of superficial lymph 
node enlargement and distant lymph node metastasis; 3) no 
abnormalities in peripheral blood cells in blood smears, in-
cluding spleen, lymph node and bone marrow. Some other 
studies also reported that the dynamic change of serum LDH 
could be used as a diagnostic marker (12). However, the value 
of LDH for the diagnosis of PHL is limited because of its poor 
specificity. Therefore, a definite diagnosis of PHL is difficult 
to establish solely based on clinical signs and symptoms. The 
imaging presentation of PHL is variable and can be a solitary 
intrahepatic  lesion,  multiple  nodules  and  diffuse  infiltra-
tion of the liver. In the imaging reports of 12 patients with 
PHL provided by Elsayes KM, et al (13), there were three cases 
of solitary nodules, one with diffuse damage, and eight with 
multiple nodular liver lesions. Multiple nodular lesions in 
liver accounted for the majority of these cases, while diffuse 
infiltration was rare. Imaging of our patient showed diffuse 
nodular lesions, and the presentation varied in ultrasound, 
CT or MRI. Therefore, there is no pathognomonic imaging 
pattern to confirm the diagnosis.
Hepatoma and metastasis from gastro-intestinal (mostly 
colon) carcinoma present very similarly and are much more 
common. Normal levels of the tumor markers, AFP and CEA 
are found in almost 100% of patients with PHL facilitating 
the differential diagnosis (3, 4, 6). The examination of the co-
lon to exclude primary colon carcinoma may be indicated. 
Thus, a definite diagnosis of PHL should include histologi-
cal and marker studies of the biopsy sample. Our patient 
presented with clinical and laboratory features which were 
suggestive for PHL; liver biopsy stained with specific immu-
no-histochemical  stains  and  flowcytometric  studies  also 
confirmed the diagnosis of PHL. There is no consensus on 
the optimal treatment for PHL. Surgical treatment, radio-
therapy and chemotherapy were all reported as treatment 
modalities alone or in combination. The prognosis of PHL 
is considered very poor with a median survival as low as 
six months for patients treated with chemotherapy alone. 
With the availability of rituximab (a monoclonal chimeric 
antibody directed against CD20 B cell antigen), chemother-
apy protocols for the treatment of PHL have dramatically 
changed in the last decade. R-CHOP protocol increased the 
complete-response rate and prolonged the survival signifi-
cantly. Unfortunately, our patient was died of complications 
of chemotherapy. Our report indicated that complications 
caused by chemotherapy still would be a major problem.
In conclusion, PHL is a rare disease, lacking specific imag-
ing and clinical manifestations and biochemical indicators. 
Its diagnosis is difficult, needing to exclude organs or tis-
sues lymphoma outside of the liver. When multiple space-
occupying lesions are found in liver but there is no any other 
organ or tissue invasion, PHL should be suspected and liver 
biopsy should be done. If the diagnosis is made, chemother-
apy should be started immediately, and adverse reactions 
and complications should be closely monitored.
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